NCT02504892: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02504892 |
|---|---|
| Title | Phase 2 Study of Everolimus Therapy in Patients With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 21, 2015 |
| Completion date | April 17, 2018 |
| Required reporting date | April 17, 2019, midnight |
| Actual reporting date | Dec. 17, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |